What is the 13F Pro Quality Score for CPIX?

13F Pro ranks CUMBERLAND PHARMACEUTICALS INC (CPIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CPIX's current score at https://13fpro.ai/research/CPIX (free sign-up required for the full ranking).

Where does 13F Pro source CPIX data?

All CUMBERLAND PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. CUMBERLAND PHARMACEUTICALS INC files with the SEC under CIK 1087294. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CPIX in?

CUMBERLAND PHARMACEUTICALS INC (CPIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CPIX research updated on 13F Pro?

CPIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CUMBERLAND PHARMACEUTICALS INC(CPIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1087294 CPIX stock profile & AI dashboard →

13F Pro Quality Score

34.6/100

Rank #2,188 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

37.9/100

Profitability

26.1/100

Balance Sheet

25.9/100

Earnings Quality

30.0/100

Free Cash Flow

70.1/100

Institutional Flow

31.5/100

Revenue Scale

9.2/100

Dilution Risk

59.4/100

CPIX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CUMBERLAND PHARMACEUTICALS INC (CPIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CPIX at 34.6/100 on a 32-signal composite quality model, placing it at rank #2,188 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (9.2) and balance sheet strength (25.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), CUMBERLAND PHARMACEUTICALS INC reports quarterly revenue of $9.1M, net income of $-3.3M, free cash flow of $387.0K. Top institutional holders of CPIX by reported 13-F value include Ikarian Capital,, RENAISSANCE TECHNOLOGIES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CPIX trades on the Nasdaq exchange and files with the SEC under CIK 1087294. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CPIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CUMBERLAND PHARMACEUTICALS INC directly from SEC EDGAR. CUMBERLAND PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 20 and 39 since 2021, currently 34.6 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about CUMBERLAND PHARMACEUTICALS INC

Quirks, history, and lore behind CPIX — the kind of stuff that makes a stock memorable.

1
The Basics
A specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Tennessee.
2
The Numbers
Annual revenue in the range of $50–60 million — not a blockbuster giant, but a scrappy niche player focused on a handful of approved hospital and acute-care drugs.
3
The History
Founded around the turn of the millennium, it was built on the idea of acquiring and developing underserved, niche hospital products that larger pharma companies had little interest in.
4
The Secret
Its portfolio targets serious conditions like gastroenterology, cardiovascular, and pain management — drugs used in the hospital rather than your neighborhood pharmacy.
5
The Lore
One of its key products, Caldolor, was the first IV ibuprofen approved in the U.S. — a surprisingly big deal for hospitals managing post-op pain without opioids.
6
The Giveaway
Named after a river and a county in Tennessee, this Nashville-based pharma quietly owns brands like Caldolor, Acetavance, and Kristalose — niche meds that keep hospitals humming.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$9.1M

Net Income

Q1 2026

$-3.3M

Free Cash Flow

Q1 2026

$387.0K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+17.6% YoY

$44.5MFY 2025

FY22 $42.0MFY23 $39.6MFY24 $37.9MFY25 $44.5M

Net Income

+56.2% YoY

$-2.8MFY 2025

FY22 $-5.6MFY23 $-6.3MFY24 $-6.5MFY25 $-2.8M

Operating Income

+56.6% YoY

$-2.8MFY 2025

FY22 $-5.7MFY23 $-9.6MFY24 $-6.4MFY25 $-2.8M

EPS (Diluted)

+58.7% YoY

$-0.19FY 2025

FY22 $-0.38FY23 $-0.44FY24 $-0.46FY25 $-0.19

Total Assets

+1.6% YoY

$76.8MFY 2025

FY22 $92.9MFY23 $81.8MFY24 $75.6MFY25 $76.8M

Total Debt

-100.0% YoY

$0.00FY 2025

FY22 —FY23 $0.00FY24 $5.1MFY25 $0.00

Op. Cash Flow

+905.7% YoY

$4.9MFY 2025

FY22 $8.5MFY23 $6.1MFY24 $-612.2KFY25 $4.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$44.5M +17.6%	$37.9M -4.3%	$39.6M -5.9%	$42.0M +16.7%	$36.0M -3.9%	$37.4M
Net Income	$-2.8M +56.2%	$-6.5M -3.2%	$-6.3M -12.7%	$-5.6M -58.8%	$-3.5M -5.0%	$-3.3M
Operating Income	$-2.8M +56.6%	$-6.4M +32.7%	$-9.6M -67.5%	$-5.7M +25.7%	$-7.7M -20.3%	$-6.4M
EPS (Diluted)	$-0.19 +58.7%	$-0.46 -4.5%	$-0.44 -15.8%	$-0.38 -58.3%	$-0.24 -9.1%	$-0.22
Total Assets	$76.8M +1.6%	$75.6M -7.6%	$81.8M -12.0%	$92.9M +10.0%	$84.5M -12.4%	$96.5M
Total Debt	$0.00 -100.0%	$5.1M	$0.00	—	—	—
Operating Cash Flow	$4.9M +905.7%	$-612.2K -110.0%	$6.1M -27.9%	$8.5M +33.3%	$6.3M +17.1%	$5.4M

Get alerted when CPIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CUMBERLAND PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CPIX

Ikarian Capital, LLC
$1.8M553,153 sh
RENAISSANCE TECHNOLOGIES LLC
$1.5M470,696 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2M361,759 sh
DIMENSIONAL FUND ADVISORS LP
$898.2K276,359 sh
PERCEPTIVE ADVISORS LLC
$640.2K196,978 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$531.3K163,468 sh
BOOTHBAY FUND MANAGEMENT, LLC
$415.0K127,694 sh
GEODE CAPITAL MANAGEMENT, LLC
$371.5K114,293 sh
J. Goldman & Co LP
$263.4K81,040 sh
Bank of New York Mellon Corp
$190.0K58,458 sh

Fund	Value	Shares
Ikarian Capital, LLC	$1.8M	553,153
RENAISSANCE TECHNOLOGIES LLC	$1.5M	470,696
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	361,759
DIMENSIONAL FUND ADVISORS LP	$898.2K	276,359
PERCEPTIVE ADVISORS LLC	$640.2K	196,978
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$531.3K	163,468
BOOTHBAY FUND MANAGEMENT, LLC	$415.0K	127,694
GEODE CAPITAL MANAGEMENT, LLC	$371.5K	114,293
J. Goldman & Co LP	$263.4K	81,040
Bank of New York Mellon Corp	$190.0K	58,458

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CPIX on your watchlist

Track score changes the day CUMBERLAND PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CPIX a good stock to buy?

13F Pro's AI-powered analysis of CUMBERLAND PHARMACEUTICALS INC (CPIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CPIX are available on the CPIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CPIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CPIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CUMBERLAND PHARMACEUTICALS INC's investment landscape.